FAST-NEUTRON RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE-CANCER - FINAL REPORT OF A RADIATION-THERAPY ONCOLOGY GROUP RANDOMIZED CLINICAL-TRIAL

被引:80
作者
LARAMORE, GE
KRALL, JM
THOMAS, FJ
RUSSELL, KJ
MAOR, MH
HENDRICKSON, FR
MARTZ, KL
GRIFFIN, TW
DAVIS, LW
机构
[1] AMER COLL RADIOL,STAT UNIT,PHILADELPHIA,PA
[2] MD ANDERSON HOSP,DEPT RADIAT ONCOL,HOUSTON,TX
[3] FERMILAB NATL ACCELERATOR LAB,MIDW INST NEUTRON THERAPY,BATAVIA,IL 60510
[4] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,BRONX,NY 10461
[5] UNIV HOSP CLEVELAND,CLEVELAND,OH 44106
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1993年 / 16卷 / 02期
关键词
NEUTRON RADIOTHERAPY; PROSTATE CANCER;
D O I
10.1097/00000421-199304000-00018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between June 1977 and April 1983 the Radiation Therapy Oncology Group (RTOG) sponsored a Phase III randomized trial investigating the use of fast neutron radiotherapy for patients with locally advanced (Stages C and D1) adenocarcinoma of the prostate gland. Patients were randomized to receive either conventional photon radiation or fast neutron radiation used in a mixed-beam (neutron/photon) treatment schedule. A total of 91 analyzable patients were entered into the study, and the two patient groups were balanced with respect to the major prognostic variables. Actuarial curves are presented for local/regional control and ''overall'' survival. Ten-year results for clinically assessed local control are 70% for the mixed-beam group versus 58% for the photon group (p = 0.03) and for survival are 46% for the mixed-beam group versus 29% for the photon group (p = 0.04). This study suggests that a regional method of treatment can influence both local tumor control and survival in patients with locally advanced adenocarcinoma of the prostate and.
引用
收藏
页码:164 / 167
页数:4
相关论文
共 22 条
[1]   ADENOCARCINOMA OF THE PROSTATE TREATED WITH EXTERNAL-BEAM RADIATION-THERAPY - 5-YEAR MINIMUM FOLLOW-UP [J].
AMDUR, RJ ;
PARSONS, JT ;
FITZGERALD, LT ;
MILLION, RR .
RADIOTHERAPY AND ONCOLOGY, 1990, 18 (03) :235-246
[2]  
BAGSHAW MA, 1985, CANCER, V55, P2079, DOI 10.1002/1097-0142(19850501)55:9+<2079::AID-CNCR2820551408>3.0.CO
[3]  
2-X
[4]   CANCER STATISTICS, 1991 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36
[5]  
COX JD, 1977, CANCER, V40, P156, DOI 10.1002/1097-0142(197707)40:1<156::AID-CNCR2820400126>3.0.CO
[6]  
2-#
[7]  
FRANK IN, 1983, CLIN ONCOLOGY MULTID, P210
[8]   PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING [J].
GLEASON, DF ;
MELLINGE.GT .
JOURNAL OF UROLOGY, 1974, 111 (01) :58-64
[9]   A 10 YEAR FOLLOW-UP OF 682 PATIENTS TREATED FOR PROSTATE-CANCER WITH RADIATION-THERAPY IN THE UNITED-STATES [J].
HANKS, GE ;
DIAMOND, JJ ;
KRALL, JM ;
MARTZ, KL ;
KRAMER, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (04) :499-505
[10]  
KAGAN AR, 1977, CANCER, V39, P637, DOI 10.1002/1097-0142(197702)39:2<637::AID-CNCR2820390240>3.0.CO